ライフサイエンスコーパス: mph

1 g memory and divided attention (MAAT/MPH>ABT/MPH).

2 dmill at 1.6, 3.2, and 4.8 km/h (1, 2, and 3 mph).

3 ng ability (SCA) and mid-parental heterosis (MPH).

4 ose sensitivity to the beneficial actions of MPH.

5 chieved when vehicle speed sustained over 45 mph.

6 ll strikes with a ball propelled at 30 to 40 mph.

7 ence+placebo and (c) 24 h smoking abstinence+MPH.

8 lar collagen surrounded by F4/80-positive MC/Mph.

9 patients who are more likely to benefit from MPH.

10 of VF with a baseball propelled at 20 to 70 mph.

11 olunteers were studied with SPECT on and off MPH.

12 tial mechanisms of the therapeutic action of MPH.

13 double-blinded, placebo-controlled trial of MPH.

14 ized in apposition to infiltrating CD11b+ Mo/Mph.

15 iC3b can modulate the cytokine profile of Mo/Mph.

16 Treatment with MPH (0.125 mg/kg), ATMX (0.125 mg/kg), or EX (3 weeks of

17 es, the effects of varying concentrations of MPH (0.25, 1.0, and 4.0 muM) on NE and DA efflux were ex

18 cross-over trial of placebo (bid), low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid), and moderate-d

19 The patients ingested a placebo (lactose) or MPH (0.6 mg/kg; 20 mg maximum) and repeated selected por

20 maximum dose, 10 mg bid), and moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid).

21 microinfusion of vehicle or varying doses of MPH (.03-8.0 mug/500 nL) directly into the dorsomedial P

22 10mg/kg); in the striatum the treatment with MPH (10mg/kg) decreased caspase-3 and cytochrome c; trea

23 hrome c were reduced in the hippocampus with MPH (10mg/kg).

24 wks) at rest and with treadmill exercise (3 mph, 15 degrees incline, 10 mins).

25 the Bcl-2 and caspase-3 were increased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg);

26 d caspase-3 and cytochrome c; treatment with MPH (2 and 10mg/kg) increased Bax and decreased Bcl-2 in

27 n of Bcl-2, caspase-3, and cytochrome c with MPH (2 and 10mg/kg); in the striatum the treatment with

28 ased with MPH (1mg/kg) and were reduced with MPH (2 and 10mg/kg); the cytochrome c was reduced in the

29 n 2 d: after ingesting a single dose of oral MPH (20 mg) or placebo (lactose) in a counterbalanced fa

30 g distance (12 blocks per week), and pace (2 mph), 26% of all new AF cases (95% CI 7% to 43%) appeare

31 For walking paces of less than 3.2 km/h (2.0 mph), 3.2 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 m

32 osed 76 people to 10, 20, 30, 40, 50, and 60 mph (4.5, 8.9, 13.4, 17.9, 22.3, and 26.8 m/s) winds in

33 o the enzyme ([Fe(2+)]PAH(R)[L-Phe,5-deaza-6-MPH(4)]), the active site converts to a five-coordinate

34 nt in children, male rats were injected with MPH (5 mg/kg) or vehicle twice daily from postnatal day

35 eceived direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100mug), amphetamine (AMPH; 0.25, 1.

36 ain any AIS > or = 2 injury was 37 kph [23.0 mph (95% CI, 32-45 kph)], and any AIS > or = 3 injury wa

37 and any AIS > or = 3 injury was 63 kph [39.1 mph (95% CI, 51-infinity kph)].

38 Methylphenidate (MPH), a commonly used dopaminergic agent, may affect ani

39 ects of orally administered methylphenidate (MPH), a first-line treatment for attention deficit hyper

40 ts of two ADHD medications, methylphenidate (MPH), a psychostimulant, and atomoxetine (ATX), a select

41 The differential action of MPH across regions disappeared at higher concentrations.

42 This work suggests that MPH, acting via noradrenergic mechanisms, can substantia

43 MPH administration improved behavioral performance and i

44 system and behavior, and also suggests that MPH administration may not have long-term consequences.

45 Finally, there were no effects of MPH administration on any reported measure.

46 Our findings indicate that MPH administration, beginning before puberty, and which

47 mining the effects of 40 mg methylphenidate (MPH) administration.

48 MPH also improved reaction times to make correct respons

49 Methylphenidate (MPH) ameliorates attention problems experienced by some

50 sive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating th

51 [(1)(1)C]MPH and [(1)(1)C]raclopride dynamic PET scans were perfo

52 ter (DAT) levels and enhances the potency of MPH and amphetamine on dopamine responses and drug-seeki

53 We found that MPH and ATX had similar effects on SICI.

54 In conclusion, MPH and ATX have similar effects on SICI in children wit

55 Both MPH and ATX increased SICI in heterozygotes but not in 1

56 ences the neurophysiological effects of both MPH and ATX.

57 erm neurobiological consequences of combined MPH and FLX treatment (MPH + FLX) during juvenile period

58 ERK2 activity within the VTA, we rescued the MPH and FLX-induced behavioral deficits seen in the forc

59 shed placebo controlled trials that compared MPH and placebo on executive and nonexecutive memory, re

60 ed decreased striatal D2R availability after MPH and these decreases were smaller in METH than in con

61 ally to reach a maximal speed of 9.7 km/h (6 mph) and a maximal inclination of 10degrees.

62 erage speed of 8.7 +/- 0.5 km/h (5.4 +/- 0.3 mph) and at an inclination of 3.3degrees +/- 2degrees.

63 se in the concurrent use of methylphenidate (MPH) and fluoxetine (FLX) in pediatric populations.

64 3.2 km/h (2.0 mph), 3.2 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 mph) or more, compared with no r

65 ning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention

66 CA and dominance-related effects for SCA and MPH, and additive-by-dominant effect for MPH was partly

67 mph impacts, to 68% with chest impact at 40 mph, and then diminished at >/=50 mph (p < 0.0001).

68 psychostimulants, including methylphenidate (MPH), are highly effective in the treatment of attention

69 se in boys newly diagnosed with ADHD predict MPH-associated changes in ADHD inattentiveness and hyper

70 Our results showed that MPH at all doses increased Bax in the cortex; the Bcl-2

71 cerebellum there was an increase of Bax with MPH at all doses, however, there was a reduction of Bcl-

72 s reduced in the cortex after treatment with MPH at all doses; in the cerebellum there was an increas

73 o, we investigated if chronic treatment with MPH at doses of 1, 2 and 10mg/kg could alter the levels

74 neurobiological consequences of exposure to MPH at high, abused doses are not well defined.

75 s with a regulation baseball delivered at 30 mph at three sites over the cardiac silhouette (i.e., di

76 The effects of methylphenidate (MPH), atomoxetine (ATMX), and/or physical exercise (EX)

77 ation (with QRS strikes) were produced by 30-mph baseball impacts to the precordium.

78 in DAT1, previously linked to ADHD risk and MPH behavioural responses, influences the neurophysiolog

79 d DA/NE re-uptake inhibitor methylphenidate (MPH), both with proven clinical efficacy in ADHD, on the

80 mposed of patients who were not administered MPH (brain tumor = 31 and acute lymphoblastic leukemia =

81 Treatment with MPH can at least temporarily reduce some attentional and

82 gest that elevated catecholamine activity by MPH can disrupt inhibitory influences on persistent risk

83 e rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and work

84 an in controls, and had no D2R changes after MPH challenge.

85 We measured the impact of MPH, compared with placebo, on behavioral and electrocor

86 mine transporter (DAT1), a site of action of MPH, could influence the effects of MPH or ATX on SICI.

87 It was not possible to resolve whether MPH delayed the initiation of the onset of puberty or re

88 lysis of human monocyte-derived macrophages (Mph) demonstrated greater susceptibility to human influe

89 Chronic MPH did not differentially alter the course of weight ga

90 with therapeutic doses of sustained release MPH did not have a significant influence on the regulati

91 be pathologies; however, in clinical trials, MPH did not improve treatment outcome in cocaine addicti

92 Impacts at 20 mph did not induce VF; incidence of VF increased increme

93 th Nile Red-positive adipocytes, we found MC/Mph distributed in cell cords, also containing various m

94 connectivity (FC) associated with the first MPH dose in boys newly diagnosed with ADHD predict MPH-a

95 inutes after the administration of the first MPH dose to 40 stimulant drug-naive boys newly diagnosed

96 s will be required to establish that the MC-/Mph-drilled tunnels evolve to become capillaries, connec

97 George W. Comstock (1915-2007), MD, MPH, DrPH, was lecturer and then professor of epidemiolo

98 Here we show in rats that exposure to MPH during pre-adolescence causes behavioral and neurobi

99 No trend was observed for MPH effectiveness in improving learning of a word associ

100 ological markers in 16 regions implicated in MPH effects and/or ADHD etiology.

101 ese findings are discussed in the context of MPH effects on the default mode network and the possible

102 A dose of 1 mg/kg intraperitoneal MPH, either single dose or chronic treatment (well withi

103 Low concentrations of MPH elicited significantly larger increases in extracell

104 MPH enhanced activity within individual neurons, ensembl

105 MPH enhances catecholamine transmission via blockade of

106 it is well established that methylphenidate (MPH) enhances sustained attention, the neural mechanisms

107 At PND135, MPH-exposed rats exhibited decreased anxiety in the elev

108 alamus neuropeptide Y-ir increased by 10% in MPH-exposed rats.

109 ats showed major structural differences with MPH exposure.

110 MPH + FLX enhanced sensitivity to drug (i.e., cocaine) a

111 MPH + FLX exposure also increased mRNA of ERK2 and its d

112 These results indicate that concurrent MPH + FLX exposure during preadolescence increases sensi

113 VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regulated protein

114 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male rats from post

115 sequences of combined MPH and FLX treatment (MPH + FLX) during juvenile periods are unknown.

116 mental area (VTA) to determine the effect of MPH, FLX, or MPH + FLX on the extracellular signal-regul

117 We administered saline (VEH), MPH, FLX, or MPH + FLX to juvenile Sprague Dawley male r

118 of these complex signals on infiltrating Mo/Mph following UV exposure, we then tested the effects of

119 treated with either 0, 2, 4, or 8 mg/kg/day MPH for 3 weeks.

120 ained sedentary or ran on a treadmill at 0.6 mph for 30 min (n = 9-12 per group) and received a bolus

121 Attention and behavioral benefits of MPH for childhood cancer survivors are maintained across

122 Funding assistance for AD's MPH from Scottish Intensive Care Society, Scottish Socie

123 In contrast, subjects treated with MPH gambled at a consistent rate, well above chance, acr

124 ebo group, the 15 patients randomized to the MPH group had a significantly greater improvement on the

125 A trend for greater improvement in the MPH group on a measure of verbal memory failed to reach

126 For the MPH group, repeated measures analysis of variance reveal

127 bal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided at

128 y working memory and divided attention (MAAT/MPH>ABT/MPH).

129 acebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory wor

130 h, those that habitually walked at a pace >3 mph had a lower risk of coronary heart disease (0.50; co

131 mental exposure to high therapeutic doses of MPH has short-term effects on select neurotransmitters i

132 Methylphenidate (MPH) has long been used to treat attention-deficit/hyper

133 Wind storms with wind speeds of up to 70 mph have not been effective in removing significant amou

134 timulant medication such as methylphenidate (MPH); however, approximately 25% of patients show little

135 f VF increased incrementally from 7% with 25 mph impacts, to 68% with chest impact at 40 mph, and the

136 is that the psychostimulant methylphenidate (MPH) improves cognitive and social functioning among the

137 , we tested for modulation of this effect by MPH in 40 healthy human adults.

138 Here, we characterized the behavior of MC/Mph in cellular infiltrates, with emphasis on their spat

139 ed premature responding whereas infusions of MPH in the core, but not the shell, sub-region significa

140 The opposing effects of ATO and MPH in the NAcb core and shell on impulsivity were unlik

141 ation of stimulants such as methylphenidate (MPH) in children with attention deficit hyperactivity di

142 ation of fluorescently labeled peritoneal MC/Mph incorporated in Matrigel-containing fluorescent prot

143 During transient inhibition, MPH increased prefrontal activation for both groups and

144 Results show that oral MPH increased responses to this salient cognitive task i

145 kg (low dose, n = 10), or (iii) 1.5 mg/kg of MPH increased to 12.5 mg/kg (high dose, n = 10) for a to

146 L/kg of vehicle (n = 10), (ii) 0.15 mg/kg of MPH increased to 2.5 mg/kg (low dose, n = 10), or (iii)

147 t increase in the parietal P3 amplitude with MPH, indicative of enhanced perceptual evidence accumula

148 The clinical application of such MPH-induced brain-behavior enhancements remains to be te

149 In these studies, MPH-induced improvement in sustained attention was aboli

150 e alpha(1)-antagonist prazosin (.5 mg/kg) on MPH-induced improvement in sustained attention was exami

151 neither in striatal D2R availability nor in MPH-induced striatal DA changes.

152 llin-1 is required for AMPH-induced, but not MPH-induced, hyperlocomotion.

153 We examined how MPH influenced known electrophysiological precursors of

154 In conclusion, our results suggest that MPH influences plasticity in the brain of young and adul

155 ssary for accurate performance in this task, MPH infusion into this region did not affect working mem

156 a novel mechanism for induction of tissue Mo/Mph into an IL-10high/IL-12low state via iC3b in combina

157 MPH is also used, without license, by healthy adults, bu

158 Methylphenidate (MPH) is a stimulant that increases extracellular levels

159 Methylphenidate (MPH) is an effective symptomatic treatment of attention

160 Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but it

161 Methylphenidate (MPH) is commonly diverted for recreational use, but the

162 Methylphenidate (MPH) is commonly prescribed for children who have been d

163 Methylphenidate (MPH) is used clinically to treat attention-deficit/hyper

164 scopicity of PM emissions at high speeds (70 mph; kappa > 1) are much larger than emissions at low sp

165 much larger than emissions at low speeds (30 mph; kappa < 0.1).

166 MPH led to an overall suppression of alpha activity acro

167 MPH led to increased rates of target detection, and elec

168 r destruction of the matrix (tunnels) and MC/Mph-lined capillary-like structures occasionally contain

169 ime, chronic modulation of young brains with MPH may exert effects on brain neurochemistry that modif

170 Although academic gains were not identified, MPH may offer benefits in academic areas not assessed.

171 Juvenile treatment with MPH may result in long-lasting, potentially permanent, c

172 <0.001; cumulative PH: MD -0.287, P <0.001; MPH: MD -0.288, P <0.001; DPH: MD -0.310, P <0.001).

173 0.010; DPH: MD -0.765, P <0.001; mesial PH [MPH]: MD -0.285, P = 0.256).

174 on was correlated with the initial 90-minute MPH-mediated FC changes.

175 at 3 months were associated with first-dose MPH-mediated FC reductions restricted to frontal-prefron

176 core improvement was associated with initial MPH-mediated FC reductions restricted to occipitoparieta

177 possible role of the default mode network in MPH-mediated improvements in inattention and hyperactivi

178 eractivity scores over the first 3 months of MPH medication was correlated with the initial 90-minute

179 To this end, we studied MC/Mph migration and assembly in basic fibroblast growth fa

180 , yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT

181 treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18).

182 In contrast to the SHRs, neither MPH nor ATMX affected orienting or social behavior in Wi

183 Methylphenidate (MPH) normalizes cortical function, enhancing task salien

184 ere measured during moderate exercise at 2.8 mph on a treadmill.

185 found no relationship between the effects of MPH on impulsivity and D2/3 receptor availability in any

186 vation period, suggesting that the impact of MPH on puberty is not permanent.

187 support the potentially important effects of MPH on various aspects of cognition known to be associat

188 ant to note that EX was just as effective as MPH or ATMX in reducing orienting behavior and social in

189 ction of MPH, could influence the effects of MPH or ATX on SICI.

190 riatum, which is normalized following either MPH or l-dopa administration.

191 th either a sustained release formulation of MPH or placebo (N=8 per group).

192 nitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment

193 (PD90) Sprague Dawley rats were treated with MPH or saline.

194 to 4.7 km/h (2.0-2.9 mph), and 4.8 km/h (3.0 mph) or more, compared with no regular walking, RRs were

195 gical enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive prob

196 and [(18)F]fallypride, rats received 6 mg/kg MPH, orally, twice each day for 28 d.

197 pact at 40 mph, and then diminished at >/=50 mph (p < 0.0001).

198 s and organogenesis and in which cells of MC/Mph phenotype play a key structural role.

199 MPH produced a broad inverted-U-shaped facilitation of s

200 Many of these MC/Mph produced MMP-12- and TIMP-1-dependent tunnels couple

201 all crashes was 29 +/- 16.9 kph [18 +/- 10.5 mph (range, 5-123 kph)].

202 When the subjects were not taking MPH, rCBF was higher in the motor, premotor, and the ant

203 In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir densi

204 MPH-related enhancements occurred without significant ch

205 MPH resulted in a statistically significant improvement

206 xamined the degree to which methylphenidate (MPH) (Ritalin) acts within distinct frontostriatal subfi

207 n rodents demonstrates that methylphenidate (MPH; Ritalin) elicits a narrow inverted-U-shaped improve

208 ousands of children receive methylphenidate (MPH; Ritalin) for attention deficit/hyperactivity disord

209 Pharmacotherapy with methylphenidate (MPH) seems to be the first-line treatment of choice in a

210 Here we show that MPH self-administration in rats increases dopamine trans

211 n mice mimics these effects, confirming that MPH self-administration-induced increases in DAT levels

212 MPH serves to reduce maladaptive electrophysiological pr

213 edial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the ca

214 However, neither ATO nor MPH significantly altered impulsive behavior when infuse

215 reversed by treatment with methylphenidate (MPH), suggesting a defect in brain catecholamine homeost

216 rom trait phenotype, and fewer QTL were from MPH than from other dependent variables.

217 xample, in comparison with a walking pace <2 mph, those that habitually walked at a pace >3 mph had a

218 The potential of monocytes/macrophages (MC/Mph) to contribute to neovascularization has recently be

219 treated with methylphenidate hydrochloride (MPH) to evaluate genetic and behavioral toxicity were ob

220 r challenge with 60 mg oral methylphenidate (MPH) (to measure DA release) to assess whether it predic

221 washout, the D2/D3 receptor availability of MPH-treated animals did not continue to decline at the s

222 the long-term neurochemical consequences of MPH treatment are unknown.

223 interaction between environment and chronic MPH treatment at clinically relevant doses, administered

224 MPH treatment increased impulsivity in LI rats, and modu

225 Brief discontinuation of MPH treatment is associated with increased motor and ant

226 Our findings suggest that MPH treatment modulates motor and anterior cingulate cor

227 ed the effects of discontinuation of chronic MPH treatment on regional cerebral blood flow (rCBF) in

228 Recovery from MPH treatment was also examined at 1, 5, and 10 weeks fo

229 Before MPH treatment, we found that D2/3 receptor availability

230 he commonly occurring brief interruptions in MPH treatment.

231 ined the effects of chronic methylphenidate (MPH) treatment on brain dopamine (DA) systems, developme

232 Eligibility criteria for the MPH trial included an estimated intelligence quotient gr

233 premedication baseline and at the end of the MPH trial while on medication.

234 on (<15 min), low-velocity ( approximately 1 mph) walking bouts.

235 Here, MPH was evaluated for its potential to alter stimulus-dr

236 ons in the core and shell, or increased when MPH was infused into either the core and shell sub-regio

237 and MPH, and additive-by-dominant effect for MPH was partly identified as additive effect; 2) the ran

238 red to placebo, significant improvement with MPH was reported by teachers and parents on the Conners'

239 ute exercise (5 minutes at 3.6, 5.9, and 9.1 mph) was performed, and hemodynamic measurements and blo

240 ated the murine poliovirus receptor homolog (Mph), was found to be a receptor for the porcine alphahe

241 The effects of varying doses of MPH were examined on performance of rats in two tests of

242 Impacts at 40 mph were more likely to produce VF than impacts with gre

243 No significant side effects from MPH were observed.

244 We also show that methylphenidate (MPH), which competitively inhibits DA uptake but does no

245 CD11b+ monocytic/macrophagic cells (Mo/Mph), which infiltrate into skin after UV irradiation, p

246 nd experiment, 20 subjects received 20 mg of MPH, while 20 matched controls received a placebo.

247 We hypothesized that oral MPH will attenuate ACC hypoactivations and improve assoc

248 le-dose, crossover study comparing 0.5 mg/kg MPH with 1.0 mg/kg ATX in 16 children with ADHD, aged 8-

249 s found for the SLC6A3 40 bp and response to MPH with only two studies selected.

250 lternatively, our findings may be related to MPH withdrawal.

251 001) and (CTB: 43 +/- 6.7 vs SCT 1.4 +/- 1.0 mpH x min(-1) x 100 ng DNA(-1), p < 0.0001).

252 0.07 to 0.20); proportion of schools with 20 mph zones (RR 1.47, 95%CI: 0.93 to 2.32), Safe Routes to